The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
We investigated the distribution of the magnetic resonance imaging (MRI)-measured response to glatiramer acetate (GA) treatment in multiple sclerosis (MS) using data from a clinical trial of relapsing-remitting (RR) MS. A fixed and a random effects model were used to quantify the between-patient heterogeneity in treatment response, expressed as new enhancing lesion percentage reduction. In 95% of the patients, lesion reduction due to treatment was estimated to range between -20% and -54%, indicating a rather homogeneous effect of GA on MRI-measured disease activity in RRMS.
Sormani
M P
MP
Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, 20132 Milan, Italy.
Bruzzi
P
P
Comi
G
G
Filippi
M
M
D001921:Brain / Q000187:drug effects / Q000473:pathology*; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D010455:Peptides / Q000627:therapeutic use*; D010919:Placebos; D012189:Retrospective Studies
D007166:Immunosuppressive Agents; D010455:Peptides; D010919:Placebos; D000068717:Glatiramer Acetate